1
|
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 2024:S0923-7534(24)00075-9. [PMID: 38490358 DOI: 10.1016/j.annonc.2024.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 03/17/2024] Open
Affiliation(s)
- T Powles
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK
| | - J Bellmunt
- Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Cancer Centre, Boston, USA
| | - E Comperat
- Department of Pathology, Medical University Vienna, Austria
| | - M De Santis
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - R Huddart
- Royal Marsden Hospital, Institute of Cancer Research, London, UK
| | - Y Loriot
- Department of Medical Oncology, Université Paris-Saclay and Gustave Roussy, Villejuif, France
| | - A Necchi
- Vita-Salute San Raffaele University, Milan; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy
| | - B P Valderrama
- Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain
| | - A Ravaud
- Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France
| | - S F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York; Department of Urology, University of Texas Southwestern, Dallas, USA; Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan
| | - B Szabados
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK
| | - M S van der Heijden
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Gillessen
- Oncology Institute of Southern Switzerland (EOC-IOSI), Bellinzona; Università della Svizzera Italina (USI), Lugano, Switzerland
| |
Collapse
|
2
|
Necchi A, Pouessel D, Leibowitz R, Gupta S, Fléchon A, García-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot Y. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol 2024; 35:200-210. [PMID: 37956738 DOI: 10.1016/j.annonc.2023.10.794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 10/17/2023] [Accepted: 10/26/2023] [Indexed: 11/15/2023] Open
Abstract
BACKGROUND Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of FGFR1-3 with antitumor activity. We report the efficacy and safety of pemigatinib in the open-label, single-arm, phase II study of previously treated, unresectable or metastatic UC with FGFR3 alterations (FIGHT-201; NCT02872714). PATIENTS AND METHODS Patients ≥18 years old with FGFR3 mutations or fusions/rearrangements (cohort A) and other FGF/FGFR alterations (cohort B) were included. Patients received pemigatinib 13.5 mg once daily continuously (CD) or intermittently (ID) until disease progression or unacceptable toxicity. The primary endpoint was centrally confirmed objective response rate (ORR) as per RECIST v1.1 in cohort A-CD. Secondary endpoints included ORR in cohorts A-ID and B, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Overall, 260 patients were enrolled and treated (A-CD, n = 101; A-ID, n = 103; B, n = 44; unconfirmed FGF/FGFR status, n = 12). All discontinued treatment, most commonly due to progressive disease (68.5%). ORR [95% confidence interval (CI)] in cohorts A-CD and A-ID was 17.8% (10.9% to 26.7%) and 23.3% (15.5% to 32.7%), respectively. Among patients with the most common FGFR3 mutation (S249C; n = 107), ORR was similar between cohorts (A-CD, 23.9%; A-ID, 24.6%). In cohorts A-CD/A-ID, median (95% CI) DOR was 6.2 (4.1-8.3)/6.2 (4.6-8.0) months, PFS was 4.0 (3.5-4.2)/4.3 (3.9-6.1) months, and OS was 6.8 (5.3-9.1)/8.9 (7.5-15.2) months. Pemigatinib had limited clinical activity among patients in cohort B. Of 36 patients with samples available at progression, 6 patients had 8 acquired FGFR3 secondary resistance mutations (V555M/L, n = 3; V553M, n = 1; N540K/S, n = 2; M528I, n = 2). The most common treatment-emergent adverse events overall were diarrhea (44.6%) and alopecia, stomatitis, and hyperphosphatemia (42.7% each). CONCLUSIONS Pemigatinib was generally well tolerated and demonstrated clinical activity in previously treated, unresectable or metastatic UC with FGFR3 mutations or fusions/rearrangements.
Collapse
Affiliation(s)
- A Necchi
- Vita-Salute San Raffaele University, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
| | - D Pouessel
- Institut Claudius Regaud-IUCT Oncopole, Toulouse, France
| | - R Leibowitz
- Chaim Sheba Medical Center, Ramat Gan; Shamir Medical Center, Zerifin, Israel
| | - S Gupta
- Huntsman Cancer Institute, Salt Lake City, USA
| | | | | | - M A Bilen
- Winship Cancer Institute of Emory University, Atlanta, USA
| | - P R Debruyne
- Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium; Medical Technology Research Centre (MTRC), School of Life Sciences, Anglia Ruskin University, Cambridge; School of Nursing and Midwifery, University of Plymouth, Plymouth, UK
| | - M I Milowsky
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
| | - T Friedlander
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
| | - M Maio
- University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy
| | | | - X Li
- Incyte Corporation, Wilmington, USA
| | - M L Veronese
- Incyte International Biosciences Sàrl, Morges, Switzerland
| | - Y Loriot
- Gustave Roussy, DITEP, Université Paris-Saclay, INSERM 981, Villejuif, France.
| |
Collapse
|
3
|
Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, Grivas P, Kamat A, Danziger N, Lin D, Huang R, Decker B, Sokol ES, Cheng L, Pavlick D, Ross JS, Bratslavsky G, Basnet A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol 2023; 41:486.e15-486.e23. [PMID: 37821306 DOI: 10.1016/j.urolonc.2023.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 08/31/2023] [Accepted: 09/03/2023] [Indexed: 10/13/2023]
Abstract
BACKGROUND Advanced bladder squamous cell carcinoma (aBSCC) is an uncommon form of urinary bladder malignancy when compared with the much higher urothelial carcinoma incidence. We studied the genomic alteration (GA) landscape in a series of aBSCC based on the association with human papilloma virus (HPV) to determine if differences in GA would be observed between the positive and negative groups. METHODS Using a hybrid capture-based FDA-approved CGP assay, a series of 171 aBSCC were sequenced to evaluate all classes of GA. Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on up to 114 loci. Programmed cell death ligand -1 (PD-L1) expression was determined by IHC (Dako 22C3) with negative expression when PD-L1 was 0, lower expression of positivity set at 1 to 49%, and higher expression set at ≥50% expression. RESULTS Overall, 11 (6.4%) of the aBSCC were found to harbor HPV sequences (10 HPV16 and 1 HPV 11). HPV+ status was identified slightly more often in women (NS) and in younger patients (P = 0.04); 2 female patients with aBSCC had a prior history of SCC including 1 anal SCC and 1 vaginal SCC. HPV+ aBSCC had fewer GA/tumor (P < 0.0001), more inactivating mutations in RB1 (P = 0.032), and fewer inactivating GA in CDKN2A (P < 0.0001), CDKN2B (P = 0.05), TERT promoter (P = 0.0004) and TP53 (P < 0.0001). GA in genes associated with urothelial carcinoma including FGFR2 and FGFR3 were similar in both HPV+ and HPV- aBSCC groups. MTAP loss (homozygous deletion) which has emerged as a biomarker for PRMT5 inhibitor-based clinical trials was not identified in any of the 11 HPV+ aBSCC cases, which was significantly lower than the 28% positive frequency of MTAP loss in the HPV- aBSCC group (P < 0.0001). MTOR and PIK3CA pathway GA were not significantly different in the 2 groups. Putative biomarkers associated with immunotherapy (IO) response, including MSI and TMB status, were also similar in the 2 groups. PD-L1 expression data was available for a subset of both HPV+ and HPV- cases and showed high frequencies of positive staining which was not different in the 2 groups. CONCLUSIONS HPV+ aBSCC tends to occur more often in younger patients. As reported in other HPV-associated squamous cell carcinomas, HPV+ aBSCC demonstrates significantly reduced frequencies of inactivating mutations in cell cycle regulatory genes with similar GA in MTOR and PIK3CA pathways. The implication of HPV in the pathogenesis of bladder cancer remains unknown but warrants further exploration and clinical validation.
Collapse
Affiliation(s)
| | | | - J Jacob
- Upstate Medical University, Syracuse, NY
| | - P E Spiess
- Department of GU Oncology, Moffitt Cancer Center, Tampa, FL
| | - R Li
- Department of GU Oncology, Moffitt Cancer Center, Tampa, FL
| | - A Necchi
- IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
| | - P Grivas
- University of Washington, Seattle, WA
| | - A Kamat
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - D Lin
- Foundation Medicine, Cambridge, MA
| | - R Huang
- Foundation Medicine, Cambridge, MA
| | - B Decker
- Foundation Medicine, Cambridge, MA
| | | | - L Cheng
- Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, RI
| | | | - J S Ross
- Upstate Medical University, Syracuse, NY
| | | | - A Basnet
- Upstate Medical University, Syracuse, NY
| |
Collapse
|
4
|
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2023; 34:289-299. [PMID: 36494006 DOI: 10.1016/j.annonc.2022.11.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 11/18/2022] [Accepted: 11/23/2022] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response and identify further safety concerns. PATIENTS AND METHODS In KEYNOTE-045, patients with metastatic UC that progressed on platinum-containing chemotherapy were randomly assigned 1:1 to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine. Primary endpoints were progression-free survival per RECIST version 1.1 by blinded independent central review (BICR) and overall survival. In KEYNOTE-052, cisplatin-ineligible patients with metastatic UC received first-line pembrolizumab. The primary endpoint was objective response rate per RECIST version 1.1 by BICR. RESULTS A total of 542 patients (pembrolizumab, n = 270; chemotherapy, n = 272) were randomly assigned in KEYNOTE-045. The median follow-up was 62.9 months (range 58.6-70.9 months; data cut-off 1 October 2020). At 48 months, overall survival rates were 16.7% for pembrolizumab and 10.1% for chemotherapy; progression-free survival rates were 9.5% and 2.7%, respectively. The median duration of response (DOR) was 29.7 months (range 1.6+ to 60.5+ months) for pembrolizumab and 4.4 months (range 1.4+ to 63.1+ months) for chemotherapy; 36-month DOR rates were 44.4% and 28.3%, respectively. A total of 370 patients were enrolled in KEYNOTE-052. The median follow-up was 56.3 months (range 51.2-65.3 months; data cut-off 26 September 2020). The confirmed objective response rate was 28.9% (95% confidence interval 24.3-33.8), and the median DOR was 33.4 months (range 1.4+ to 60.7+ months); the 36-month DOR rate was 44.8%. Most treatment-related adverse events for pembrolizumab in either study were grade 1 or 2 and manageable, which is consistent with prior reports. CONCLUSION With ∼5 years of follow-up, pembrolizumab monotherapy continued to demonstrate durable efficacy with no new safety signals in patients with platinum-resistant metastatic UC and as first-line therapy in cisplatin-ineligible patients. CLINICAL TRIAL REGISTRY AND ID With ClinicalTrials.gov NCT02256436 (KEYNOTE-045); https://clinicaltrials.gov/ct2/show/NCT02256436 and NCT02335424 (KEYNOTE-052); https://clinicaltrials.gov/ct2/show/NCT02335424.
Collapse
Affiliation(s)
- A V Balar
- Perlmutter Cancer Center, New York University Langone Health, New York, USA
| | - D E Castellano
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Grivas
- Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle
| | - D J Vaughn
- Division of Hematology/Oncology, Abramson Cancer Center, Penn Medicine, Philadelphia, USA
| | - T Powles
- Department of Genitourinary Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - J Vuky
- Department of Medicine/Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, USA
| | - Y Fradet
- Department of Surgery/Urology, CHU de Québec-Université Laval, Québec City, Canada
| | - J-L Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - L Fong
- Department of Medicine, University of California San Francisco, San Francisco
| | - N J Vogelzang
- Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA
| | - M A Climent
- Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, València, Spain
| | - A Necchi
- Department of Medical Oncology, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy
| | - D P Petrylak
- Department of Internal Medicine/Medical Oncology, Smilow Cancer Hospital, Yale New Haven Health, New Haven, USA
| | - E R Plimack
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
| | - J Z Xu
- Department of Medical Oncology, Merck & Co., Inc., Rahway, USA
| | - K Imai
- Department of Medical Oncology, Merck & Co., Inc., Rahway, USA
| | - B H Moreno
- Department of Medical Oncology, Merck & Co., Inc., Rahway, USA
| | - J Bellmunt
- Department of Hematology and Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - R de Wit
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
| | - P H O'Donnell
- Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, USA.
| |
Collapse
|
5
|
Rowe I, Larcher A, Belladelli F, Lucianò R, Sant’Angelo M, Doglioni C, Colecchia M, Bernardi R, Simoni M, Necchi A, Marandino L, Pipitone G, Carrera P, Re C, Cei F, Fallara G, Scotti G, Franco I, Briganti A, Montorsi F, Capitanio U, Salonia A. Renal tumor heterogeneity analysis in Von Hippel-Lindau disease using single-cell RNA sequencing. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01078-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
6
|
Basile G, Leni R, Re C, Pellegrino F, Scilipoti P, Longoni M, Cannoletta D, Necchi A, Gandaglia G, Salonia A, Briganti A, Montorsi F, Moschini M. The black box of intraoperative adverse incident reporting during radical cystectomy: Not only post-operative complications matter. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00205-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Rosiello G, Re C, Cei F, Basile G, Musso G, Fallara G, Belladelli F, Cignoli D, Canibus D, Soares Pinto S, Necchi A, Marandino L, Karakiewicz P, Rowe I, Villa G, Boarin M, Disabato N, Trevisani F, Bettiga A, Briganti A, Montorsi F, Salonia A, Larcher A, Capitanio U. Frailty Index in predicting surgical outcomes after partial nephrectomy in patients with renal cell carcinoma. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00892-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
8
|
Nocera L, Bandini M, Basile G, Moschini M, Naidu S, Rose K, Li R, Spiess P, Necchi A. Chemotherapy vs. immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01330-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Reike M, Raggi D, Marandino L, Patanè D, Crupi E, Costa De Padua T, Black P, Gibb E, Necchi A. Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01203-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
10
|
Mazzone E, Gandaglia G, Stabile A, Robesti D, Necchi A, Cirulli G, Pellegrino A, Scuderi S, Raggi D, Marandino L, Barletta F, De Angelis M, Cucchiara V, Rosiello G, Sorce G, Pellegrino F, Longoni M, Scilipoti P, Fossati N, Montorsi F, Briganti A. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01153-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
11
|
Re C, Belladelli F, Cei F, Salerno L, Cusano S, Innace F, Pipitone G, Carrera P, Russo Raucci A, Patricelli M, Falini A, De Cobelli F, Mortini P, Bandello F, Lattanzio R, Falconi M, Partelli S, Necchi A, Marandino L, Rowe I, Montorsi F, Capitanio U, Larcher A, Salonia A. Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: Results from a prospective observational study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00388-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
12
|
Baiamonte G, Rosiello G, Cei F, Tenace N, Musso G, Basile G, Re C, Fallara G, Belladelli F, Cignoli D, Colecchia M, Rowe I, De Cobelli F, Pennella R, Della Corte A, Brembilla G, Bertini R, Briganti A, Necchi A, Montorsi F, Salonia A, Larcher A, Lucianò R, Capitanio U. The current role of renal tumor biopsy in the management of small renal masses: Long-term results from a prospective, single-institutional database. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01315-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
13
|
Fallara G, Martini A, Rosiello G, Belladelli F, Musso G, Cei F, Basile G, Re C, Cignoli D, De Cobelli F, Brembilla G, Marandino L, Raggi D, Gandaglia G, Mazzone E, Moschini M, Stabile A, Briganti A, Necchi A, Montorsi F, Salonia A, Larcher A, Capitanio U. Defining the most useful intermediate endpoint for overall survival in intermediate and high-risk clear cell carcinoma. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00517-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
14
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Necchi A, Raggi D, Marandino L, Cirulli G, Scuderi S, Barletta F, De Angelis M, Balestrazzi E, Fanti S, Cucchiara V, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01159-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
15
|
Necchi A, Li R, Rose K, Davaro F, Davaro E, Spiess P, Petros G, Bratslavsky G, Jacob J, Pavlick D, Ross J, Huang R, Lin D, Danziger N, Graf R. CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00588-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
16
|
Belladelli F, Re C, Cei F, Musso G, Fallara G, Basile G, Rosiello G, Cignoli D, Canibus D, Bertini A, Bertini R, Lucianò R, Tenace N, Necchi A, Raggi D, Marandino L, Montorsi F, Salonia A, Briganti A, Guazzarotti G, Brembilla G, De Cobelli F, Capitanio U, Larcher A. Clinical benefit and cost-effectiveness of a biopsy-all strategy in patients diagnosed with renal mass: Simulation of a randomized controlled trial. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01314-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
17
|
Musso G, Basile G, Nini A, Rosiello G, Fallara G, Re C, Cei F, Belladelli F, Cignoli D, Canibus D, Soares Pinto S, Rowe I, Lucianò R, Tenace N, Salonia A, Briganti A, Matloob R, Bertini R, Necchi A, Marandino L, Raggi D, Montorsi F, Larcher A, Capitanio U. Venous tumour thrombus in renal cell carcinoma: Locally advanced or metastatic disease? Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00380-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
18
|
Avesani G, Pellegrino F, Re C, Leni R, Basile G, Scilipoti P, Longoni M, Cannoletta D, Gandaglia G, Capitanio U, Colombo R, Necchi A, Raggi D, Salonia A, Briganti A, Montorsi F, Moschini M. Impact of neoadjuvant immune-checkpoint inhibitor on intra and post operative outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01331-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
19
|
Mazzone E, Gandaglia G, Stabile A, Robesti D, Necchi A, Raggi D, Marandino L, Cirulli G, Scuderi S, Barletta F, Pellegrino A, De Angelis M, Cucchiara V, Rosiello G, Sorce G, Nocera L, Pellegrino F, Longoni M, Scilipoti P, Quarta L, Gallina A, Fossati N, Montorsi F, Briganti A. Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01158-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
20
|
Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, López JA, Montesion M, Nimeiri H, Parikh AR, Roychowdhury S, Schwemmers S, Silverman IM, Vogel A. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 2022; 7:100641. [PMID: 36462464 PMCID: PMC9832751 DOI: 10.1016/j.esmoop.2022.100641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 10/24/2022] [Accepted: 10/25/2022] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND Selective tyrosine kinase inhibitors targeting fibroblast growth factor receptor (FGFR) 1-4 genomic alterations are in development or have been approved for FGFR-altered cancers (e.g. bladder cancer and advanced intrahepatic cholangiocarcinoma). Understanding FGFR inhibitor-resistance mechanisms is increasingly relevant; we surveyed the pan-tumor landscape of FGFR1-4 genomic alterations [short variants (SVs), gene rearrangements (REs), and copy number alterations (CNAs)], including their association with tumor mutational burden (TMB) and the genomic comutational landscape. PATIENTS AND METHODS Comprehensive genomic profiling of 355 813 solid tumor clinical cases was performed using the FoundationOne and FoundationOne CDx assays (Foundation Medicine, Inc.) to identify genomic alterations in >300 cancer-associated genes and TMB (determined on ≤1.1 megabases of sequenced DNA). RESULTS FGFR1-4 SVs and REs occurred in 9603/355 813 (2.7%), and CNAs in 15 078/355 813 (4.2%) samples. Most common FGFR alterations for bladder cancer, intrahepatic cholangiocarcinoma, and glioma were FGFR3 SVs (1051/7739, 13.6%), FGFR2 REs (618/6641, 9.3%), and FGFR1 SVs (239/11 550, 2.1%), respectively. We found several, potentially clinically relevant, tumor-specific associations between FGFR1-4 genomic alterations and other genomic markers. FGFR3 SV-altered bladder cancers and FGFR1 SV-altered gliomas were significantly less likely to be TMB-high versus unaltered samples. FGFR3 SVs in bladder cancer significantly co-occurred with TERT and CDKN2A/B alterations; TP53 and RB1 alterations were mutually exclusive. In intrahepatic cholangiocarcinoma, FGFR2 REs significantly co-occurred with BAP1 alterations, whereas KRAS, TP53, IDH1, and ARID1A alterations were mutually exclusive. FGFR1 SVs in gliomas significantly co-occurred with H3-3A and PTPN11 alterations, but were mutually exclusive with TERT, EGFR, TP53, and CDKN2A/B alterations. CONCLUSIONS Overall, our hypothesis-generating findings may help to stratify patients in clinical trials and guide optimal targeted therapy in those with FGFR alterations.
Collapse
Affiliation(s)
- K Murugesan
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - A Necchi
- Genitourinary Medical Oncology, Vita-Salute San Raffaele University, Milan; Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
| | - T C Burn
- Translational and Data Sciences, Incyte Corporation, Wilmington
| | - O Gjoerup
- Scientific and Medical Publications, Foundation Medicine, Inc., Cambridge, USA
| | - R Greenstein
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - M Krook
- Research Scientist, Ohio State University, Columbus, USA
| | - J A López
- Integrated Healthcare Solutions, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - M Montesion
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - H Nimeiri
- Global Clinical Development Lead Oncology, Foundation Medicine, Inc., Cambridge, USA
| | - A R Parikh
- Oncology (Medical/Hematology), Jefferson Health, Philadelphia, USA
| | | | - S Schwemmers
- Integrated HealthCare Solutions PDMA (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - I M Silverman
- Clinical Bioinformatics, Incyte Corporation, Wilmington
| | - A Vogel
- Clinic for Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany.
| |
Collapse
|
21
|
Necchi A, Bajorin D, Tomita Y, Ye D, Agerbaek M, Enting D, Peer A, Milowsky M, Kobayashi K, Grimm MO, Stenner F, David J, Li J, Chasalow S, Nasroulah F, Apfel A, Ünsal-Kaçmaz K, Galsky M. Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase 3 CheckMate 274 trial. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02582-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
22
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Necchi A, Raggi D, Marandino L, Cirulli G, Scuderi S, Barletta F, De Angelis M, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01280-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
23
|
Nocera L, Basile G, Leni R, de Angelis M, Martini A, Avesani G, Scuderi S, Gandaglia G, Dehò F, Gallina A, Raggi D, Marandino L, Necchi A, Montorsi F, Briganti A, Moschini M. The impact of variant histology on the probability of lymph node involvement at imaging: CT scan vs FDG PET. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01023-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Re C, Rosiello G, Fallara G, Basile G, Cignoli D, Martini A, De Cobelli F, Brembilla G, Nocera L, Belladelli F, Colandrea G, Canibus D, Musso G, Cei F, Matloob R, Briganti A, Bertini R, Necchi A, Raggi D, Karakiewicz P, Montorsi F, Salonia A, Larcher A, Capitanio U. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01256-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Cucchiara V, Mazzone E, Robesti D, Gandaglia G, Stabile A, Scuderi S, Leni R, Barletta F, Nocera L, Necchi A, Raggi D, Marandino L, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01242-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
Basile G, Bandini M, Raggi D, Marandino L, Colombo R, Avesani G, Colecchia M, Lucianò R, Moschini M, Briganti A, Montorsi F, Necchi A. Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: final results from the pure-01 study. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01125-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
27
|
Avesani G, Mazzone E, Robesti D, Gandaglia G, Stabile A, Scuderi S, Martini A, Bravi C, Rosiello G, Nocera L, Sorce G, Pellegrino F, Cirulli G, D’Ambrosio L, Necchi A, Raggi D, Marandino L, Montorsi F, Briganti A. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01087-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
28
|
Fallara G, Rosiello G, Necchi A, Raggi D, Cazzaniga W, Martini A, Basile G, Cignoli D, Colandrea G, Baiamonte G, Belladelli F, Musso G, Cei F, Giancristofaro C, Ieva A, Canibus D, Briganti A, Bertini R, Montorsi F, Salonia A, Larcher A, Capitanio U. Oncologic outcomes in patients diagnosed with PT3A non-metastatic renal cell cancer according to renal vein thrombus or fat invasion. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01257-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Necchi A, Murugesan K, Burn T, Gjoerup O, Greenstein R, López J, Montesion M, Nimeiri H, Parikh A, Roychowdhury S, Schwemmers S, Silverman I, Vogel A. 100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
30
|
Padua T, Basile G, Bandini M, Raggi D, Marandino L, Giannatempo P, Colombo R, Colecchia M, Lucianò R, Moschini M, Briganti A, Montorsi F, Necchi A. 1738P Three-year follow-up update and survival outcomes of the PURE-01 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
31
|
Necchi A, Bajorin D, Tomita Y, Ye D, Agerbæk M, Enting D, Peer A, Milowsky M, Kobayashi K, Grimm MO, Stenner-Liewen F, David J, Li J, Chasalow S, Nasroulah F, Apfel A, Unsal-Kacmaz K, Galsky M. 1737MO Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
32
|
De Wit R, Vaughn D, Fradet Y, Fong L, Vogelzang N, Climent Duran M, Necchi A, Petrylak D, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Bajorin D, Choueiri T, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL. 1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
33
|
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:244-258. [PMID: 34861372 DOI: 10.1016/j.annonc.2021.11.012] [Citation(s) in RCA: 179] [Impact Index Per Article: 89.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 11/16/2021] [Accepted: 11/17/2021] [Indexed: 12/24/2022] Open
Affiliation(s)
- T Powles
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK
| | - J Bellmunt
- Beth Israel Deaconess Medical Centre-IMIM Lab, Harvard Medical School, Boston, USA
| | - E Comperat
- L'Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - M De Santis
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - R Huddart
- Royal Marsden Hospital, Institute of Cancer Research, London, UK
| | - Y Loriot
- Département de Médecine Oncologique, Université Paris-Saclay and Gustave Roussy, Villejuif, France
| | - A Necchi
- Vita-Salute San Raffaele University, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy
| | | | - A Ravaud
- Hôpital Saint-André CHU, Bordeaux, France; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France
| | - S F Shariat
- Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
| | - B Szabados
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital, London, UK
| | - M S van der Heijden
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - S Gillessen
- Oncology Institute of Southern Switzerland (IOSI), EOC, Lugano, Switzerland
| |
Collapse
|
34
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Rosiello G, Bravi C, Martini A, Cirulli G, Pellegrino A, De Angelis M, Necchi A, Raggi D, Cucchiara V, Suardi N, Shariat S, Montorsi F, Briganti A. The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and 68Ga-PSMA PET/CT scan. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00285-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Scuderi S, Barletta F, Nocera L, Leni R, Marandino L, Raggi D, Necchi A, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00277-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
De Angelis M, Mazzone E, Gandaglia G, Stabile A, Scuderi S, Barletta F, Robesti D, Nocera L, Leni R, Cucchiara V, Necchi A, Zaffuto E, Suardi N, Shariat S, Montorsi F, Briganti A. Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: Results from a large single, referral center series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00912-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Fallara G, Rosiello G, Raggi D, Marandino L, Malena G, Basile G, Colandrea G, Cignoli D, Belladelli F, Musso G, Cei F, Bertini R, Briganti A, Salonia A, Montorsi F, Larcher A, Necchi A, Capitanio U. Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01079-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Rosiello G, Fallara G, Basile G, Cignoli D, De Cobelli F, Brambilla G, Nocera L, Belladelli F, Colandrea G, Canibus D, Re C, Musso G, Cei F, Giancristofaro C, Briganti A, Bertini R, Necchi A, Raggi D, Mottrie A, Karakiewicz P, Montorsi F, Salonia A, Larcher A, Capitanio U. The anatomical location of lymphadenopathies at imaging predicts the risk of lymph node invasion at final pathology in patients with renal cell carcinoma. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01068-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Nocera L, Basile G, Leni R, De Angelis M, Martini A, Scuderi S, Gandaglia G, Mottrie A, Gallina A, Raggi D, Marandino L, Necchi A, Montorsi F, Briganti A, Moschini M. The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00976-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Necchi A, Pavlick D, Bratslavsky G, Jacob J, Kravtsov O, Spiess P, Grivas P, Parini V, Decker B, Lin D, Danziger N, Levy M, Ross J. Expanding the use of targeted therapy for Urothelial Bladder Cancer (UBC): Non-FGFR3 Receptor Tyrosine Kinase (RTK) Gene Rearrangements (ReAr) and Fusions (Fus). Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00986-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Mazzone E, Robesti D, Gandaglia G, Stabile A, Cucchiara V, Bravi C, Necchi A, Raggi D, Marandino L, Cirulli G, Balestrazzi E, Fanti S, Cucchiara V, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00742-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Nini A, Trevisani F, Bettiga A, Fallara G, Rosiello G, Martini A, Nocera L, Belladelli F, Baiamonte G, Cazzaniga W, Rowe I, Canibus D, Musso G, Cei F, Giancristofaro C, Briganti A, Bertini R, Necchi A, Montorsi F, Salonia A, Larcher A, Capitanio U. Clinical outcomes of patients with renal cell carcinoma and imperative indication to become anephric: Implications for multidisciplinary board evaluation. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00227-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Rosiello G, Baiamonte G, Fallara G, Basile G, Luciano R, Colecchia M, Martini A, Cignoli D, Nocera L, Belladelli F, Colandrea G, Canibus D, Re C, Musso G, Cei F, Briganti A, Bertini R, Necchi A, Raggi D, Karakiewicz P, Montorsi F, Salonia A, Larcher A, Capitanio U. The added value of histological subtype in the prediction of oncologic outcomes in patients with non-metastatic papillary renal cell carcinoma. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00136-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Martini A, Raggi D, Joshi H, Fallara G, Nocera L, Belladelli F, Montorsi F, Necchi A, Galsky M. Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma and the potential impact of informative censoring. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00980-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Rosiello G, Fallara G, Basile G, Martini A, Cignoli D, Nocera L, Belladelli F, Colandrea G, Canibus D, Re C, Musso G, Cei F, Giancristofaro C, Briganti A, Bertini R, Necchi A, Raggi D, Karakiewicz P, Montorsi F, Salonia A, Larcher A, Capitanio U. The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00292-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Basile G, Rosiello G, Fallara G, Pellegrino A, Larcher A, Raggi D, Campi R, Pal S, Spiess P, Montorsi F, Choueiri T, Necchi A, Capitanio U. Sustainable multidisciplinary team referral for non-metastatic renal cell carcinoma: A survival-based recommendation. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01078-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
47
|
Lonati C, Mordasini L, Afferi L, De Cobelli O, Di Trapani E, Necchi A, Briganti A, Montorsi F, Simeone C, Zamboni S, Simone G, Karnes R, Marra G, Soria F, Gontero P, Shariat S, Hendrickesn K, Rink M, Poyet C, Carando R, Krajewski W, Baumeister P, Mattei A, Moschini M. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology – Young Academic Urologists. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00836-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Lainé-caroff P, Ouzaïd I, Moschini M, Hendricksen K, Kassouf W, Baumann B, Noon A, Ploussard G, Necchi A, Hermieu J, Sargos P, Xylinas E. Impact de la récidive locale et métastatique sur la survie des patients traités par cystectomie totale ayant des marges chirurgicales positives sur les tissus mous. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Necchi A, Galsky M, Shore N, Plimack E, Jia C, Homet Moreno B, Witjes J. Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03213-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
50
|
Fallara G, Cristodoro M, Tutolo M, Necchi A, Cannoletta D, Rosiello G, Messina A, Briganti A, Gallina A, Montorsi F, Salonia A. Pre-surgical multiparametric magnetic resonance imaging features predicting continence after robotic radical cystectomy with orthotopic bladder reconstruction: preliminary findings form PURE-01 trial. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00805-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|